Laigo Bio Secures €17M: SureTACs Platform Targets Cancer, Autoimmune Diseases
March 31, 2026, 3:34 pm
Laigo Bio secured €17M seed funding for its SureTACs platform. The biotech pioneers precision membrane protein degradation. Funds will accelerate oncology programs to the clinic. They also advance autoimmune and immunology candidates. The innovative technology targets disease-causing proteins. It offers new hope for previously untreatable conditions. Global investors back this cutting-edge European firm. This capital propels next-generation therapeutics forward.
Utrecht, The Netherlands, hosts Laigo Bio. This innovative biotech firm made headlines. It recently closed its seed financing round. The company secured a total of €17 million. This substantial capital injection fuels groundbreaking research. It targets previously undruggable disease mechanisms.
The final tranche added €5.5 million. Biovance Capital emerged as a new co-lead investor, committing €4 million. Existing co-lead Kurma Partners contributed an additional €1.5 million. This round validates Laigo Bio’s advanced platform. It signals strong investor confidence. An initial close occurred in December 2025.
Laigo Bio spearheads precision medicine. Its core innovation is the SureTACs™ platform. SureTACs stands for Surface Removal Targeting Chimeras. This proprietary technology develops highly specialized therapies. It targets disease-causing membrane proteins. The goal is complete elimination.
The SureTACs platform represents a significant leap. It generates bispecific antibodies. These antibodies perform a dual function. They pair an optimal E3 ligase. This ligase links to a specific disease-causing target protein. This pairing triggers ubiquitination. Ubiquitination marks the protein for destruction. Lysosomal degradation then breaks it down. This process offers unparalleled specificity.
This precision is crucial. It minimizes off-target effects. It enhances therapeutic efficacy. The platform focuses on eliminating disease-driving membrane targets. Such targets are often challenging. Many are considered "undruggable" by conventional methods. Laigo Bio's approach opens new therapeutic avenues. It aims for first-in-class, dual-targeted therapies.
The newly secured funds have a clear purpose. They will accelerate oncology programs. These vital programs move closer to clinical development. Cancer treatment remains a critical unmet need. Laigo Bio’s novel approach offers new hope. It could redefine cancer therapy.
Beyond oncology, the company advances other programs. Three candidate programs target autoimmune and immunology indications. Graft rejection is also a key focus area. Autoimmune diseases affect millions. They present complex therapeutic challenges. SureTACs technology could provide precise solutions.
The investor syndicate supporting Laigo Bio is robust. It comprises prominent venture capital firms. Besides Biovance Capital and Kurma Partners, other investors include Curie Capital and Argobio Studio. Angelini Ventures, Eurazeo, Oncode Bridge Fund, ROM Utrecht Region, and Cancer Research Horizons also participate. This diverse backing underscores the platform’s broad appeal. It also highlights its scientific merit.
The addition of Dr. João Incio to the Board of Directors strengthens Laigo Bio's leadership. Dr. Incio is a General Partner at Biovance Capital. His expertise will guide strategic development. This further validates the company's trajectory. It ensures robust governance and insight.
Targeted protein degradation is a burgeoning field. It promises a revolution in drug discovery. Laigo Bio positions itself at the forefront. Its SureTACs platform offers unique advantages. It tackles membrane proteins directly. This differentiates it from other degradation approaches. These often focus on intracellular proteins.
The company's scientific foundation is strong. It developed the SureTACs platform in conjunction with leading institutions. Prof. Madelon Maurice’s laboratory at the UMC Utrecht contributed significantly. The Oncode Institute also played a key role. This collaboration ensures scientific rigor. It fosters continuous innovation.
Laigo Bio addresses massive global health challenges. Cancer remains a leading cause of death. Autoimmune diseases impose significant burdens. Current treatments often lack specificity. They carry severe side effects. The need for better, safer therapies is urgent. SureTACs aims to fill this void.
The acceleration of programs towards the clinic is a critical milestone. It means potential therapies move closer to patients. This journey is complex. It requires significant capital. It demands scientific excellence. Laigo Bio demonstrates both. Its progress offers real promise.
The biotech landscape is competitive. Innovation drives success. Laigo Bio's focus on "first-in-class" therapies is strategic. It seeks to create entirely new treatment options. This differentiates it from incremental improvements. This ambition is a hallmark of truly transformative companies.
The global biotechnology market closely watches developments like SureTACs. Protein degradation technologies represent a paradigm shift. They move beyond blocking protein function. They instead eliminate the disease-causing protein entirely. This direct approach could offer more durable effects. It could lead to superior patient outcomes.
Laigo Bio’s success underscores European biotech strength. The Netherlands is a growing hub for life sciences. Its scientific ecosystem fosters innovation. This funding round demonstrates global confidence in European research. It highlights the potential for global impact from regional excellence.
Looking forward, Laigo Bio's trajectory is clear. The company will advance its lead candidates. It will expand its pipeline. It will continue to explore new targets. This robust funding provides the necessary runway. It ensures sustained growth and development. The promise of precision membrane protein degradation is immense. Laigo Bio is poised to deliver on this promise. The future of treating complex diseases may soon change. This biotech firm leads the charge.
Utrecht, The Netherlands, hosts Laigo Bio. This innovative biotech firm made headlines. It recently closed its seed financing round. The company secured a total of €17 million. This substantial capital injection fuels groundbreaking research. It targets previously undruggable disease mechanisms.
The final tranche added €5.5 million. Biovance Capital emerged as a new co-lead investor, committing €4 million. Existing co-lead Kurma Partners contributed an additional €1.5 million. This round validates Laigo Bio’s advanced platform. It signals strong investor confidence. An initial close occurred in December 2025.
Laigo Bio spearheads precision medicine. Its core innovation is the SureTACs™ platform. SureTACs stands for Surface Removal Targeting Chimeras. This proprietary technology develops highly specialized therapies. It targets disease-causing membrane proteins. The goal is complete elimination.
The SureTACs platform represents a significant leap. It generates bispecific antibodies. These antibodies perform a dual function. They pair an optimal E3 ligase. This ligase links to a specific disease-causing target protein. This pairing triggers ubiquitination. Ubiquitination marks the protein for destruction. Lysosomal degradation then breaks it down. This process offers unparalleled specificity.
This precision is crucial. It minimizes off-target effects. It enhances therapeutic efficacy. The platform focuses on eliminating disease-driving membrane targets. Such targets are often challenging. Many are considered "undruggable" by conventional methods. Laigo Bio's approach opens new therapeutic avenues. It aims for first-in-class, dual-targeted therapies.
The newly secured funds have a clear purpose. They will accelerate oncology programs. These vital programs move closer to clinical development. Cancer treatment remains a critical unmet need. Laigo Bio’s novel approach offers new hope. It could redefine cancer therapy.
Beyond oncology, the company advances other programs. Three candidate programs target autoimmune and immunology indications. Graft rejection is also a key focus area. Autoimmune diseases affect millions. They present complex therapeutic challenges. SureTACs technology could provide precise solutions.
The investor syndicate supporting Laigo Bio is robust. It comprises prominent venture capital firms. Besides Biovance Capital and Kurma Partners, other investors include Curie Capital and Argobio Studio. Angelini Ventures, Eurazeo, Oncode Bridge Fund, ROM Utrecht Region, and Cancer Research Horizons also participate. This diverse backing underscores the platform’s broad appeal. It also highlights its scientific merit.
The addition of Dr. João Incio to the Board of Directors strengthens Laigo Bio's leadership. Dr. Incio is a General Partner at Biovance Capital. His expertise will guide strategic development. This further validates the company's trajectory. It ensures robust governance and insight.
Targeted protein degradation is a burgeoning field. It promises a revolution in drug discovery. Laigo Bio positions itself at the forefront. Its SureTACs platform offers unique advantages. It tackles membrane proteins directly. This differentiates it from other degradation approaches. These often focus on intracellular proteins.
The company's scientific foundation is strong. It developed the SureTACs platform in conjunction with leading institutions. Prof. Madelon Maurice’s laboratory at the UMC Utrecht contributed significantly. The Oncode Institute also played a key role. This collaboration ensures scientific rigor. It fosters continuous innovation.
Laigo Bio addresses massive global health challenges. Cancer remains a leading cause of death. Autoimmune diseases impose significant burdens. Current treatments often lack specificity. They carry severe side effects. The need for better, safer therapies is urgent. SureTACs aims to fill this void.
The acceleration of programs towards the clinic is a critical milestone. It means potential therapies move closer to patients. This journey is complex. It requires significant capital. It demands scientific excellence. Laigo Bio demonstrates both. Its progress offers real promise.
The biotech landscape is competitive. Innovation drives success. Laigo Bio's focus on "first-in-class" therapies is strategic. It seeks to create entirely new treatment options. This differentiates it from incremental improvements. This ambition is a hallmark of truly transformative companies.
The global biotechnology market closely watches developments like SureTACs. Protein degradation technologies represent a paradigm shift. They move beyond blocking protein function. They instead eliminate the disease-causing protein entirely. This direct approach could offer more durable effects. It could lead to superior patient outcomes.
Laigo Bio’s success underscores European biotech strength. The Netherlands is a growing hub for life sciences. Its scientific ecosystem fosters innovation. This funding round demonstrates global confidence in European research. It highlights the potential for global impact from regional excellence.
Looking forward, Laigo Bio's trajectory is clear. The company will advance its lead candidates. It will expand its pipeline. It will continue to explore new targets. This robust funding provides the necessary runway. It ensures sustained growth and development. The promise of precision membrane protein degradation is immense. Laigo Bio is poised to deliver on this promise. The future of treating complex diseases may soon change. This biotech firm leads the charge.